Short Interest Coverage: What’s Ahead for Trevena Incorporated (NASDAQ:TRVN) After More Shorted Shares?

November 18, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Coverage: What’s Ahead for Trevena Incorporated (NASDAQ:TRVN) After More Shorted Shares?

The stock of Trevena Incorporated (NASDAQ:TRVN) registered an increase of 3.43% in short interest. TRVN’s total short interest was 1.57M shares in November as published by FINRA. Its up 3.43% from 1.52 million shares, reported previously. With 239,200 shares average volume, it will take short sellers 7 days to cover their TRVN’s short positions. The short interest to Trevena Incorporated’s float is 4.58%. The stock decreased 0.63% or $0.04 during the last trading session, hitting $6.32. Trevena Inc (NASDAQ:TRVN) has declined 30.93% since April 18, 2016 and is downtrending. It has underperformed by 35.36% the S&P500.

Trevena Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $345.42 million. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors . It currently has negative earnings. Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Trevena Inc (NASDAQ:TRVN) Ratings Coverage

Out of 7 analysts covering Trevena Inc (NASDAQ:TRVN), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Trevena Inc has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Cowen & Co maintained Trevena Inc (NASDAQ:TRVN) rating on Tuesday, September 1. Cowen & Co has “Outperform” rating and $14 price target. The company was maintained on Tuesday, August 11 by Needham. The firm has “Buy” rating given on Wednesday, March 2 by WallachBeth Capital. JMP Securities maintained it with “Market Outperform” rating and $18 target price in Wednesday, March 9 report. On Monday, August 3 the stock rating was initiated by Brean Capital with “Buy”. The company was maintained on Wednesday, September 2 by JMP Securities. The stock has “Equal-Weight” rating given by Barclays Capital on Tuesday, September 1. FBR Capital initiated the shares of TRVN in a report on Tuesday, March 29 with “Outperform” rating.

TRVN Company Profile

Trevena Inc., incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. In addition to these three product candidates, it has identified and has completed the Phase I program for TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.

Another recent and important Trevena Inc (NASDAQ:TRVN) news was published by Businesswire.com which published an article titled: “Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine …” on February 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>